Recent News

Health Canada authorizes Gazyva® (obinutuzumab) for adults with active lupus nephritis

On January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for the treatment of adult...

FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

With this approval, pediatric patients aged five years and older with active lupus nephritis will...

The Canada Disability Benefit (CDB)

The Canada Disability Benefit (CDB) is an important step forward to improving Canada’s social safety...

FDA Accepts Supplemental Biologics License Application for Gayzva for Treatment of Lupus Nephritis

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA)...

Obinutuzumab Shows Positive Results for Lupus Nephritis

Lupus Ontario is excited to share share positive news of the Phase 3 REGENCY clinical...

PHASE III Results for Roche’s Regency Study by Roche

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people...

Managing Work, Relationships, & Lupus – Finding the Right Balance by Elizabeth Lo Serro

Living with lupus means constantly adjusting to the fluctuating demands of your health, your career,...

Lupus Ontario funds certification for Advanced Clinician Practitioner in Arthritis Care (ACPAC) in Thunder Bay

In 2023, Vanessa Cava and Abbey Hunter organized the Thunder Bay WALK for Lupus Ontario....